Cancer Control and Survivorship Program

项目摘要/摘要--癌症控制和生存方案 癌症控制和生存计划(CCSP)的首要目标是进行高度创新 临床、遗传学和观察性研究，并将我们的发现转化为有效的策略，以避免或 减少与治疗相关的并发症，提高儿童癌症幸存者的生活质量。莱斯利博士 流行病和癌症控制部主任L.Robison和美国疾病控制与预防中心主任Melissa Hudson 癌症存活部，领导该计划。他们在CCSP的两个NCI资助的队列中的领导作用， 圣裘德终身队列研究(SJLIFE)和儿童癌症幸存者研究(CCSS)，促进了 表征儿童癌症发病率的大小和范围的开创性发现， 包括由此产生的慢性病和随后的肿瘤的负担及其对早产的影响 死亡率。从这项研究中获得的知识影响了当代儿科癌症的设计 治疗战略，并提供关键数据以指导健康监测和保健干预 为长期幸存者准备的。CCSP是围绕广泛的共享研究基础设施构建的，旨在 支持和加强计划成员进行的研究。这一基础设施反映了 以部门为重点的资源，加上机构和SJCCC特定资源以及临床资源 机构外部的服务。CCSP共有16名成员(11名正式成员和5名准成员)，代表 流行病学和癌症控制、肿瘤学、心理学、全球儿科医学和 儿科医学。创新研究的设计和实施由7个特定学科的CCSP推动 工作组：神经科学、心肺、内分泌-生殖、遗传学、全球结果、 心理社会-行为和流行病学-生物统计学，定期开会(双周或 每月)。在当前赠款期间(2013-2017)，共同国家战略计划成员积极参与 计划性的研究合作。CCSP成员发表的研究论文总数为424篇，并展示了 计划的高度协作性，50%反映了计划内，25.9%反映了计划间 程序性协作。在本供资期间，共同国家方案成员启动/进行了试验。 处理加强对高危幸存者进行健康筛查的方法，促进积极的健康行为， 纠正治疗导致的认知缺陷，减少疲劳，总共有2283人参加了 介入非治疗性试验。其中许多试验反映了观察性研究的直接转化 由CCSP成员进行。CCSP成员参加了各种各样的多组协作 (NCI指定的20多个癌症中心、NCI癌症流行病学和遗传学部门、 儿童肿瘤学小组和多个国际中心)，以确定治疗和遗传因素 具有特定后遗症的高风险。CCSP成员每年的同行评审总额为420万美元 资金，包括NCI提供的410万美元资金。

PROJECT SUMMARY/ABSTRACT—Cancer Control and Survivorship Program The overarching goal of the Cancer Control and Survivorship Program (CCSP) is to conduct highly innovative clinical, genetic, and observational research, and translate our findings into effective strategies to avert or mitigate treatment-related complications and improve the quality of life of childhood cancer survivors. Drs. Leslie L. Robison, chair of the Department of Epidemiology and Cancer Control, and Melissa Hudson, director of the Division of Cancer Survivorship, lead the Program. Their leadership roles in the CCSP's two NCI-funded cohorts, St. Jude Lifetime Cohort Study (SJLIFE) and the Childhood Cancer Survivor Study (CCSS), have facilitated seminal discoveries characterizing the magnitude and scope of morbidity of the childhood cancer experience, including the resulting burden of chronic disease and subsequent neoplasms and their contribution to premature mortality. Knowledge gained from this research has influenced the design of contemporary pediatric cancer treatment strategies and provided critical data to guide health surveillance and health preserving interventions for long-term survivors. The CCSP is structured around an extensive shared research infrastructure designed to support and enhance the research conducted by Program members. This infrastructure reflects a combination of departmental-focused resources, augmented by institutional and SJCCC-specific resources plus clinical services external to the institution. The CCSP has a total of 16 members (11 Full and 5 Associate), representing the Departments of Epidemiology & Cancer Control, Oncology, Psychology, Global Pediatric Medicine, and Pediatric Medicine. The design and conduct of innovative research is facilitated by 7 discipline-specific CCSP working groups: Neurosciences, Cardiopulmonary, Endocrine-Reproductive, Genetics, Global Outcomes, Psychosocial-Behavioral, and Epidemiology-Biostatistics, who meet on a regular schedule (bi-weekly or monthly). During the current grant period (2013-2017), CCSP members have actively engaged in intra- and inter- programmatic research collaborations. Research publications by CCSP members totaled 424 and demonstrate the highly collaborative nature of the Program with 50% reflecting an intra-programmatic and 25.9% inter- programmatic collaboration. During the current funding period, CCSP members initiated/conducted trials addressing approaches to enhance health screening for at-risk survivors, promote positive health behaviors, remediate treatment-induced cognitive deficits, and reduce fatigue, contributing a total of 2283 enrollments to interventional non-therapeutic trials. Many of these trials reflect a direct translation of observational research conducted by CCSP members. CCSP members have participated in a wide variety of multi-group collaborations (involving more than 20 NCI-designated Cancer Centers, the NCI Division of Cancer Epidemiology and Genetics, the Children's Oncology Group, and multiple international centers) to characterize treatment and genetic factors conferring high risk for specific late effects. CCSP members have a total of $4.2M in annual peer-reviewed funding, including $4.1M in NCI funding.